During the preparation of this work the authors used the webtool on HOME for Researchers ( to polish the language
Image from the 3D body scanner showing a 2.3 inch or 6.6% decrease in waist circumference over 4 months.
Rodriguez DR, endible A, Gomez N, and et al
Three FDA-approved GLP-1 medications are eligible under the bridge program when used to reduce excess body weight and maintain weight reduction: Wegovy (semaglutide), available as a weekly injection or daily oral tablet, manufactured by Novo Nordisk Zepbound (tirzepatide), available in the KwikPen autoinjector format, manufactured by Eli Lilly Foundayo (orforglipron), the first non-peptide, small-molecule oral GLP-1 for weight loss, recently FDA-approved and manufactured by Eli Lilly Each of these medications works by mimicking the activity of glucagon-like peptide-1, a hormone that regulates appetite, fullness, and blood sugar